Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 10, 2026
Why Is International Business Machines (IBM) Stock Up +0.73% Today?

Why Is International Business Machines (IBM) Stock Up +0.73% Today?

Key Takeaways

  • IBM shares are trading 0.73% higher on Monday, rising to $239.02 from Friday's close of $237.28, extending a V-shaped recovery from July's post-earnings lows.
  • The stock continues to benefit from bargain hunting and an improving technical picture following a brutal July selloff that erased roughly 25% of its market value in a single session.
  • Investors appear to be looking past near-term headwinds — including securities fraud investigations and declining mainframe revenue — toward IBM's resilient software growth and expanding AI and quantum computing portfolios.
  • Today also marks the record date for IBM's $1.69 quarterly dividend, underscoring the stock's appeal to income-oriented investors amid a yield now hovering near 2.9%.
  • Broader market sentiment and sector rotation into beaten-down enterprise technology names have provided additional tailwinds for IBM's ongoing rebound.

Opening Summary

IBM, the Armonk, New York-based technology and consulting giant, is trading modestly higher on Monday, gaining approximately 0.73% to $239.02 as of midday, compared with Friday's closing price of $237.28. While the session's move is not explosive, it marks a continuation of the stock's methodical recovery from its July collapse, when preliminary second-quarter results and a sharp downward revision in growth expectations triggered the company's worst single-day decline since the 1987 market crash. The stock has now clawed back roughly 13% from its 52-week low of $199.19 hit in late July.

A V-Shaped Recovery Gains Traction

Monday's advance is the latest chapter in what technical analysts describe as a V-shaped rebound for IBM. After plummeting from a 52-week high of $332.46 in early June to below $200 in late July, the stock has strung together a series of positive sessions, recovering more than 10% from its trough. The rally has been fueled by a combination of short-covering, value-oriented buying, and growing recognition that the July selloff — while justified by disappointing Q2 results — may have overshot to the downside.

Second-quarter revenue of $17.16 billion, reported on July 22, fell short of the $17.46 billion consensus, dragged down by a 42% year-over-year collapse in IBM Z mainframe revenue and flat consulting growth. Yet software — now IBM's primary growth engine at roughly 45% of revenue — grew 5% year-over-year, with Red Hat accelerating to 11% growth and the company's GenAI book of business surpassing $12.5 billion inception-to-date. Management also maintained its free cash flow growth target of approximately $1 billion for the full year, a signal of underlying financial resilience.

Dividend Record Date and Income Appeal

Monday, August 10, also serves as the record date for IBM's quarterly dividend of $1.69 per share, with payment scheduled for September 10. With the stock yielding approximately 2.9% — elevated after the recent price decline — IBM's 31-year streak of consecutive dividend increases remains a powerful draw for income-focused investors. The dividend is well-covered, consuming roughly 40% of projected 2026 free cash flow of approximately $15.7 billion, providing a margin of safety that income investors prize.

AI, Quantum, and Government Cloud Catalysts

Beyond the recovery trade, IBM has recently unveiled several initiatives that bolster its long-term growth narrative. Its Apptio subsidiary previewed "IBM Apptio AI Value & ROI," a tool designed to help enterprises track and justify AI spending by linking token costs to measurable business outcomes. Separately, IBM's Maximo Application Suite as a Service received FedRAMP Moderate authorization, opening the door for U.S. federal agencies to adopt its cloud-based asset management tools. In quantum computing, IBM announced a definitive agreement to acquire HRL Laboratories and reported progress demonstrating computational advantages on logical quantum circuits in collaboration with the University of Chicago.

Market Context and Trading Activity

Monday's session aligns with a broader tone of stabilization across technology equities. IBM continues to trade below both its 50-day simple moving average of approximately $258 and its 200-day moving average near $255, signaling that the stock remains in a technical downtrend on a longer timeframe despite the near-term rebound. Year-to-date, IBM is still down roughly 20%, dramatically underperforming the S&P 500. However, the stock's low beta of approximately 0.70 has attracted defensive positioning from investors seeking technology exposure with reduced volatility.

What Comes Next for IBM

The path forward for IBM hinges on several key variables. The company's third-quarter earnings report, expected around October 21, will be critical in validating — or undermining — management's assertion that second-half revenue growth will reaccelerate toward the high end of the revised 4% to 5% constant-currency guidance range. Wall Street's consensus rating remains a "Moderate Buy," with an average price target of approximately $265, though several analysts — including Morgan Stanley at $190 and HSBC at $191 — maintain a far more cautious stance. Ongoing securities fraud investigations by multiple law firms into IBM's pre-announcement disclosures represent an unresolved legal overhang, while the pace of deal closures in consulting and the trajectory of the mainframe product cycle will heavily influence sentiment in the months ahead.

Trending AI Robots

Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each employing distinct strategies, timeframes, and performance metrics calibrated to current market environments. Only the strongest-performing bots under prevailing conditions are highlighted in the curated Trending AI Robots section, giving traders a dynamic view of which algorithms are delivering results right now. Whether you follow momentum, value, or technical patterns, exploring the Trending AI Robots page can help you identify data-driven approaches aligned with today's market conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBM

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


IBM's RSI Indicator recovers from oversold territory

The RSI Indicator for IBM moved out of oversold territory on July 24, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on IBM as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBM just turned positive on July 31, 2026. Looking at past instances where IBM's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBM advanced for three days, in of 375 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IBM moved below its 50-day moving average on July 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBM crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.489) is normal, around the industry mean (7.266). P/E Ratio (21.073) is within average values for comparable stocks, (71.568). IBM's Projected Growth (PEG Ratio) (2.415) is slightly higher than the industry average of (1.199). Dividend Yield (0.028) settles around the average of (0.025) among similar stocks. P/S Ratio (3.268) is also within normal values, averaging (146.459).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 9.28B. The market cap for tickers in the group ranges from 0 to 223.55B. IBM holds the highest valuation in this group at 223.55B. The lowest valued company is ARSC at 0.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was 4%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 48%. CACI experienced the highest price growth at 29%, while CYCU experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 65
Price Growth Rating: 58
SMR Rating: 72
Profit Risk Rating: 93
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
IBM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of various computer products through the use of advanced information technology

Industry InformationTechnologyServices

Profile
Details
Industry
Information Technology Services
Address
One New Orchard Road
Phone
+1 914 499-1900
Employees
305300
Web
http://www.ibm.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.